Cancer

Self-order option boosts colorectal cancer screening rates

Thursday, January 21, 2021 - 5:01pm

PASADENA, Calif., Jan. 21, 2021 /PRNewswire/ --A study among Kaiser Permanente members in Southern California shows that allowing patients to self-order a colorectal cancer screening test online improves rates of testing completion.

Key Points: 
  • PASADENA, Calif., Jan. 21, 2021 /PRNewswire/ --A study among Kaiser Permanente members in Southern California shows that allowing patients to self-order a colorectal cancer screening test online improves rates of testing completion.
  • If we can increase our colorectal cancer screening rates even by a little, we could have an enormous impact on reducing colorectal cancer mortality, Dr. Hahn said.
  • Kaiser Permanente recommends annual at-home colorectal cancer screening for patients between the ages of 50 and 74 years of age, who have had no history of colorectal cancer, have not completed colorectal cancer screening within the past 12 months, and have not completed a colonoscopy within the past 10 years, or sigmoidoscopy within the past 5 years.
  • The study cohort included 176,231 participants between 50 and 74 years of age who were eligible for colorectal cancer screening.

Global Cancer Gene Therapy Market Research during 2021-2025 | Industry Planning Analysis for the New Normal | Technavio

Thursday, January 21, 2021 - 3:26pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005646/en/
    Technavio has announced its latest market research report titled Global Cancer Gene Therapy Market 2021-2025 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your business?
  • The report on the cancer gene therapy market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The cancer gene therapy market analysis includes the application and geography landscape.
  • The cancer gene therapy market covers the following areas:

Stand Up To Cancer Announces $3.25 Million In Grants For Research To Improve Treatment Of Head And Neck Cancers

Thursday, January 21, 2021 - 2:00pm

The grants include contributions of $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation.

Key Points: 
  • The grants include contributions of $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation.
  • The American Head and Neck Society and the Head and Neck Cancer Alliance are each providing $125,000 to support the project.
  • The grants will support new approaches to treating head and neck cancers, especially those associated with Fanconi anemia and human papillomavirus, or HPV.
  • "Oral, head and neck cancers together make up the sixth most common cancer diagnosed worldwide," said Amanda Hollinger, executive director of the Head and Neck Cancer Alliance.

Global Liver Cancer Therapeutics Market to 2025 by Cancer Type, Therapy, Equipment, Age, Factors, Route of Administration, Distribution Channel, Region, Competition, Forecast & Opportunities

Thursday, January 21, 2021 - 1:30pm

According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.

Key Points: 
  • According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.
  • Expensive treatments as well as high cost in research and development might hamper further development of liver cancer therapeutics market.
  • The Global Liver Cancer Therapeutics Market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • The oral segment is anticipated to dominate the Global Liver Cancer Therapeutics Market during the forecast period as it is most preferred route of administration for chemotherapy.

CairnSurgical Announces First Patient Treated in Pivotal Clinical Trial of Breast Cancer Locator System

Thursday, January 21, 2021 - 1:00pm

CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

Key Points: 
  • CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.
  • The Breast Cancer Locator (BCL) Study is a prospective, multicenter, 1:1 randomized, controlled pivotal trial of breast cancer excision surgery in 448 women with non-palpable invasive breast cancer or ductal carcinoma in situ (DCIS) tumors treated at up to 15 U.S. centers.
  • We developed the Breast Cancer Locator with the vision to provide improved clinical outcomes in order to reduce the positive margin rate.
  • CairnSurgicals Breast Cancer Locator System enables precise tumor localization and excision, and has been tested in both single arm and randomized clinical trials.

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Thursday, January 21, 2021 - 1:05pm

(Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Key Points: 
  • (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.
  • Salarius lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.

Reaching new heights by working together: Innovative industry partnership using artificial intelligence to improve survival rates of cancer diagnosed patients

Thursday, January 21, 2021 - 1:00pm

It is the second leading cause of cancer death in Canadians and is responsible for more deaths than breast cancer or prostate cancer.

Key Points: 
  • It is the second leading cause of cancer death in Canadians and is responsible for more deaths than breast cancer or prostate cancer.
  • Were confident that artificial intelligence will bring tremendous added-value in improving treatment to stage IV cancer patients, declares Diane Ct, CEO of MEDTEQ+.
  • This innovative new partnership demonstrates Quebecs continued leadership in the field of artificial intelligence applied in health care.
  • Its mission is to accelerate the development of innovative technological solutions to improve patients health and quality of life.

Kanazawa University research: Potential combined drug therapy for lung cancer

Thursday, January 21, 2021 - 11:23am

KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.

Key Points: 
  • KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.
  • This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.
  • Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer.
  • However, in certain scenarios where gene alterations occur, the drug has an adverse effect, as now shown by Azusa Tanimoto from Kanazawa University and colleagues.

Kanazawa University research: Potential combined drug therapy for lung cancer

Thursday, January 21, 2021 - 11:20am

KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.

Key Points: 
  • KANAZAWA, Japan, Jan. 21, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable.
  • This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.
  • Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer.
  • However, in certain scenarios where gene alterations occur, the drug has an adverse effect, as now shown by Azusa Tanimoto from Kanazawa University and colleagues.

DGAP-News: Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening

Thursday, January 21, 2021 - 10:01am

"By denying coverage for the only FDA approved blood test at this time, a portion of Medicare beneficiaries will needlessly die of colorectal cancer.

Key Points: 
  • "By denying coverage for the only FDA approved blood test at this time, a portion of Medicare beneficiaries will needlessly die of colorectal cancer.
  • Despite the egregious decision by CMS, the Company will continue to pursue a leadership position in the colorectal cancer screening market and in liquid biopsy technology.
  • Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer.
  • Epi proLung(R), a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.